{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-10-15&answer.answeringMemberPrinted=George+Freeman", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2014-10-15&answer.answeringMemberPrinted=George+Freeman", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-10-15&_metadata=all&answer.answeringMemberPrinted=George+Freeman", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-10-15&_page=0&answer.answeringMemberPrinted=George+Freeman", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-10-15&answer.answeringMemberPrinted=George+Freeman", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2014-10-15&answer.answeringMemberPrinted=George+Freeman", "items" : [{"_about" : "http://data.parliament.uk/resources/100022", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100022/answer", "answerText" : {"_value" : "<p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.<\/p><p> <\/p><p> <\/p><p> <\/p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-21T16:00:56.1397924Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Patient Choice Schemes"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to promote patient choice.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4104", "label" : {"_value" : "Biography information for Neil Carmichael"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stroud"}
      , "tablingMemberPrinted" : [{"_value" : "Neil Carmichael"}
      ], "uin" : "905559"}
    , {"_about" : "http://data.parliament.uk/resources/93556", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93556/answer", "answerText" : {"_value" : "<p>The Pharmaceutical Price Regulation Scheme (PPRS) as agreed with the Association of the British Pharmaceutical Industry (ABPI) does not cover the onward financial flows of payments to the National Health Service which are subject to the Government accounting and budgeting rules in the normal way. In particular there was no agreement to hypothecate PPRS payments. The Department has subsequently had a number of discussions with the ABPI and NHS England about the onward financial flows.<\/p><p> <\/p><p> <\/p><p> <\/p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the mandate and as such were included within commissioner allocations. The same is expected to apply in 2015-16. This means that the effect of the deal is felt across the NHS through the general funding allocations to clinical commissioning groups.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the ABPI are discussing how best to improve access to and optimise patient outcomes from these medicines.<\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p><p><strong> <\/strong><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-22T15:38:43.80669Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what discussions (a) he or (b) officials in his Department have had on reinvesting the industry rebate payments under the current Pharmaceutical Price Regulation Scheme into (i) healthcare services and (ii) medicines expenditure.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3931", "label" : {"_value" : "Biography information for Dr Julian Huppert"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Julian Huppert"}
      ], "uin" : "210807"}
    , {"_about" : "http://data.parliament.uk/resources/93563", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93563/answer", "answerText" : {"_value" : "<p>A working group, chaired by NHS England and including patient representatives, clinical representatives, the Department and the Medicines and Healthcare Products Regulatory Agency, has been set up to understand and address the concerns which have been raised about transvaginal mesh implants.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-22T15:19:50.645981Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Surgical Mesh Implants"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will review his policy on polypropylene transvaginal mesh implants in response to recent court judgements in the US.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/523", "label" : {"_value" : "Biography information for Mr Nicholas Brown"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne East"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Nicholas Brown"}
      ], "uin" : "210655"}
    , {"_about" : "http://data.parliament.uk/resources/93566", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93566/answer", "answerText" : {"_value" : "<p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014 and £76 million in respect of the second quarter. The Department will publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first two quarters PPRS payments were published in June and September 2014 respectively and can be found on the Government\u2019s website at:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information\" target=\"_blank\">https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information<\/a><\/p><p> <\/p><p> <\/p><p> <\/p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-20T16:15:30.8911788Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the value is of the rebate payments made by industry under the Pharmaceutical Price Regulation Scheme to date; and what proportion of that rebate has been reinvested in (i) healthcare services and (ii) medicines expenditure.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3931", "label" : {"_value" : "Biography information for Dr Julian Huppert"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Julian Huppert"}
      ], "uin" : "210640"}
    , {"_about" : "http://data.parliament.uk/resources/93568", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93568/answer", "answerText" : {"_value" : "<p>The Government has funding mechanisms in place for research and development relating to cancer treatments.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the use of natural products in cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The NIHR is investing £16 million over five years (to 2017) in 14 Experimental Cancer Medicine Centres (ECMCs) across England with joint funding from Cancer Research UK. These centres bring together laboratory and clinical patient-based research to speed up the development of innovative cancer therapies and individualise patient treatment. Researchers at the Leicester ECMC are currently looking at whether curcumin \u2013 found in turmeric \u2013 can improve drug response in patients with advanced bowel cancer.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR and is not currently funding any studies of the use of natural products in cancer treatment.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to UK academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-22T15:10:04.2140072Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what funding his Department provides for businesses and organisations conducting research into the benefits of natural products in cancer therapy and treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1388", "label" : {"_value" : "Biography information for Lord Dodds of Duncairn"}
      }
      , "tablingMemberConstituency" : {"_value" : "Belfast North"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Nigel Dodds"}
      ], "uin" : "210719"}
    , {"_about" : "http://data.parliament.uk/resources/93570", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93570/answer", "answerText" : {"_value" : "<p>Information is not available in the format requested<\/p><p> <\/p><p> <\/p><p> <\/p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "210703"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-22T15:33:24.5802945Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Diabetes"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with diabetes in (a) England and (b) Havering in 2013-14.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
      }
      , "tablingMemberConstituency" : {"_value" : "Romford"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
      ], "uin" : "210702"}
    , {"_about" : "http://data.parliament.uk/resources/93571", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93571/answer", "answerText" : {"_value" : "<p>Information is not available in the format requested<\/p><p> <\/p><p> <\/p><p> <\/p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "210702"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-22T15:33:24.4531158Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Thyroid Gland"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with myxodema in (a) England and (b) Havering in 2013-14.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
      }
      , "tablingMemberConstituency" : {"_value" : "Romford"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
      ], "uin" : "210703"}
    , {"_about" : "http://data.parliament.uk/resources/93573", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93573/answer", "answerText" : {"_value" : "<p>Prior to April 2013, information on the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority (SHA) and data on spend through the Fund in each city was not collected. Information on spend by the North West SHA and in England in 2010-11, 2011-12 and 2012-13 is shown in the following table:<\/p><p> <\/p><p> <\/p><p> <\/p><table><tbody><tr><td><p> <\/p><\/td><td><p>Amount Spent (£000)<\/p><p>2010-11<\/p><\/td><td><p>Amount Spent (£000)<br> 2011-12<\/p><\/td><td><p>Amount Spent (£000)<br> 2012-13<\/p><\/td><\/tr><tr><td><p>North West SHA<\/p><\/td><td><p>7,400<\/p><\/td><td><p>10,015<\/p><\/td><td><p>29,272<\/p><\/td><\/tr><tr><td><p>England<\/p><\/td><td><p>38,254<\/p><\/td><td><p>108,327<\/p><\/td><td><p>175,334<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p><em>Source<\/em>: Information provided to the Department by SHAs<\/p><p> <\/p><p> <\/p><p> <\/p><p>NHS England has had oversight of the Fund since April 2013 and does not collect information at city level. In 2013-14, £63,368,429 was spent through the Fund in the North of England region and total national expenditure in England, net of any central rebates, was £230,539,005. Figures for 2014-15 are not currently available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-20T16:20:31.8199947Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer Drugs Fund: Liverpool"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what proportion of the cancer drugs fund has been spent in Liverpool since its inception.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4035", "label" : {"_value" : "Biography information for Steve Rotheram"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Walton"}
      , "tablingMemberPrinted" : [{"_value" : "Steve Rotheram"}
      ], "uin" : "210689"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 8, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}